OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
Planned Phase 2 Studies in Ulcerative Colitis and Sjögren’s Syndrome to Start in 2020
Before you continue, please confirm the following:
Professional advisers only
I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.
We use cookies to improve your experience on our website
Information we collect about your use of Goldea Capital website
Goldea Capital website collects personal data about visitors to its website.
When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.
Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.